Enclomiphene has become a staple of men's-health telehealth marketing and fitness social media, pitched as 'natural TRT' — a pill that raises your own testosterone instead of replacing it with injections or gel, while preserving fertility. The mechanism behind that pitch is legitimate. Enclomiphene is the trans-isomer of clomiphene, a selective estrogen receptor modulator that blocks estrogen feedback at the hypothalamus and pituitary, driving up luteinizing hormone (LH) and follicle-stimulating hormone (FSH) and, in turn, endogenous testosterone.
Randomised trial data support the core claims. In a phase II randomised study in men with secondary hypogonadism, enclomiphene citrate raised total testosterone while increasing LH and FSH, and — unlike topical testosterone, which suppressed sperm production — it preserved sperm counts. Later phase III work and meta-analyses reproduced the testosterone rise with fertility preservation, the key differentiator versus conventional testosterone replacement, which shuts down the HPG axis.
Where the 'natural TRT' framing outruns the evidence is regulatory status. Enclomiphene is not an FDA-approved drug. Repros Therapeutics sought approval for a branded version (Androxal) and received Complete Response Letters, with the FDA in December 2015 saying the phase III design was no longer adequate to demonstrate clinical benefit and asking for additional studies. It is dispensed in the US only through compounding pharmacies, which are not held to the same premarket review as approved products.
Calling it 'natural' is also imprecise. Enclomiphene is a synthetic SERM, closely related to a decades-old fertility drug, not a supplement. Reported side effects mirror clomiphene — mood changes, visual disturbances and, in some men, no meaningful benefit. The practical takeaway is that the pharmacology is sound and trial-backed for a specific population, but the marketing compresses 'raises your own testosterone' into 'natural and proven', which the FDA record does not.